Primary mediastinal large B-cell lymphoma

Primary mediastinal large B-cell lymphoma (PMBL) is a type of non-Hodgkin lymphoma that originates in the mediastinum, the area in the chest between the lungs. It is a rare subtype of diffuse large B-cell lymphoma (DLBCL), accounting for approximately 2-4% of all non-Hodgkin lymphomas.

Symptoms

The most common symptoms of PMBL are cough, shortness of breath, and chest pain. Other symptoms may include night sweats, fever, and weight loss, which are known as B symptoms in the context of lymphoma.

Diagnosis

Diagnosis of PMBL typically involves a combination of imaging studies, biopsy, and laboratory tests. Imaging studies such as chest X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan can help to identify the location and extent of the lymphoma. Biopsy of the tumor is necessary to confirm the diagnosis and determine the specific type of lymphoma. Laboratory tests can provide additional information about the patient's overall health and how the lymphoma is affecting the body.

Treatment

Treatment for PMBL usually involves chemotherapy, often in combination with radiation therapy. The specific regimen of chemotherapy drugs used can vary, but often includes a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), sometimes with the addition of the monoclonal antibody rituximab (R-CHOP). In some cases, stem cell transplantation may be considered as a treatment option.

Prognosis

The prognosis for PMBL is generally favorable, with a 5-year survival rate of approximately 70-80%. However, the prognosis can vary depending on a number of factors, including the patient's age, overall health, and response to treatment.

See also

• Non-Hodgkin lymphoma
• Diffuse large B-cell lymphoma
• Mediastinum
• Chemotherapy
• Radiation therapy